Radiation before surgery for high-risk upper urinary tract cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether giving radiation therapy before surgery can improve outcomes for people with high-risk upper urinary tract cancer. It aims to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with high-risk upper urinary tract cancer that has not spread to other parts of the body.
- You are willing to have surgery to remove the cancer and are able to follow the treatment plan.
- You have not had radiation therapy to your pelvis or abdomen before.
- You have not had chemotherapy for this cancer before.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use reliable birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs and radiation therapy given before surgery for high-risk upper tract urothelial cancer. The goal is to see if this approach can improve outcomes for patients who are eligible for surgery.
This trial tests whether adding radiation therapy after surgery that removes only part of the ureter or the entire kidney and ureter helps prevent cancer from coming back in patients who have high-risk features like aggressive cell type or deep tumor invasion.
This trial is testing whether adding immunotherapy and radiation after surgery can improve outcomes for people with advanced upper tract urothelial cancer (UTUC) who cannot have chemotherapy. It compares the combination to surgery alone.
This trial compares combining immunotherapy with radiation versus standard chemotherapy for patients with high-risk upper urinary tract cancer after surgery. It aims to see if the new combination works better at preventing cancer from coming back.
This trial is testing a kidney-sparing treatment approach for people with high-risk cancer in the kidney or ureter that has not spread. It aims to control the cancer while saving as much of the kidney's function as possible.
This trial tests whether combining the immunotherapy drug tislelizumab with the chemotherapy drug nab-paclitaxel before surgery can help treat high-risk upper tract urothelial cancer. The goal is to shrink the tumor and improve outcomes for patients who are planning to have their kidney and ureter removed.
Hear when a new Urothelial Carcinoma of the Renal Pelvis and Ureter trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.